The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Effectiveness and Safety of Dabigatran and Warfarin in Real‐World US Patients With Non‐Valvular Atrial Fibrillation: A Retrospective Cohort Study
Open accessAbstract
Background: The recent availability of dabigatran, a novel oral anticoagulant, provided a new treatment option for stroke prevention in atrial fibrillation beyond warfarin, the main therapy for years. Little is known about their real‐world comparative effectiveness and safety, even less among patient demographic and clinical subgroups. Methods and Results: Using a cohort of non‐valvular AF patients initiating anticoagulation from October 2010 to December 2012 drawn from a large US database of commercial and Medicare supplement claims, we applied propensity score weights to Cox proportional hazards regression to assess the comparative effectiveness and safety of dabigatran versus warfarin. Analyses were repeated among clinical and demographic subgroups using stratum‐specific propensity scores as an exploratory analysis. Of the 64 935 patients initiating anticoagulation, 32.5% used dabigatran. Compared with warfarin, dabigatran was associated with a lower risk of ischemic stroke or systemic embolism (composite adjusted Hazard Ratio [ aHR ], 95% CI : 0.86, 95% CI : 0.79 to 0.93), hemorrhagic stroke ( aHR : 0.51, 0.40 to 0.65), and acute myocardial infarction ( aHR : 0.88, 95% CI : 0.77 to 0.99), and no relation was seen between dabigatran and the composite harm outcome ( aHR : 0.94, 95% CI : 0.87 to 1.01). However, dabigatran was associated with a higher risk of gastrointestinal bleeding ( aHR : 1.11, 95% CI : 1.02 to 1.22). Estimates of effectiveness and safety appeared to be mostly similar across subgroups. Conclusions: Dabigatran could be a safe and potentially more effective alternative to warfarin in patients with atrial fibrillation managed in routine practice settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Austin, P. C. (2009) · Statistics in Medicine · doi:10.1002/sim.3697 · Cited by 6,758 · cited 1×
“The absolute standardized difference was also used to compare the baseline characteristics between warfarin and dabigatran users, whereby significant imbalance of baseline characteristics between groups is usually characterized by an absolute standardized difference >10.(18) We estimated adjusted hazard ratios (aHRs)…”
MethodEffect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Friberg, L., Rosenqvist, M., & Lip, G. Y. H. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr488 · Cited by 1,192
Graham, D. J., Reichman, M. E., Wernecke, M., Zhang, R., Southworth, M. R., Levenson, M., Sheu, T.-C., Mott, K., Goulding, M. R., Houstoun, M., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.012061 · Cited by 644
Adherence: Comparison of Methods to Assess Medication Adherence and Classify Nonadherence
Hansen, R. A., Kim, M. M., Song, L., Tu, W., Wu, J., & Murray, M. D. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l496 · Cited by 274 · cited 1×
“However, refill records are generally a widely accepted means of assessing medication exposure and have been shown to have good validity, correlation, and similar sensitivity and specificity with other measurements, including self-report, pill counts, and electronic records.(35,36) In addition, information about morta…”
ResultPancholy, S. B., Sharma, P. S., Pancholy, D. S., Patel, T. M., Callans, D. J., & Marchlinski, F. E. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.10.035 · Cited by 204
Cited by
Desai, R. J., & Franklin, J. M. (2019) · BMJ · doi:10.1136/bmj.l5657 · Cited by 657
Yao, X., Abraham, N. S., Sangaralingham, L. R., Bellolio, M. F., McBane, R. D., Shah, N. D., & Noseworthy, P. A. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003725 · Cited by 419
Brieger, D., Amerena, J., Attia, J., Bajorek, B., Chan, K. H., Connell, C., Freedman, B., Ferguson, C., Hall, T., Haqqani, H., et al. (2018) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2018.06.1043 · Cited by 327
Vinogradova, Y., Coupland, C., Hill, T., & Hippisley-Cox, J. (2018) · BMJ · doi:10.1136/bmj.k2505 · Cited by 275
Macle, L., Cairns, J., Leblanc, K., Tsang, T., Skanes, A., Cox, J. L., Healey, J. S., Bell, A., Pilote, L., Andrade, J. G., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.591 · Cited by 272
Metadata
- Authors
- Lauffenburger, J. C., Farley, J. F., Gehi, A. K., Rhoney, D. H., Brookhart, M. A., & Fang, G.
- Venue
- Journal of the American Heart Association
- Published
- 2015-04-22
- Volume
- 4
- Issue
- 4
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2159229357
- Cited by
- 158
- References
- 8
- FWCI
- 21.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.